Platinum-Sensitive Ovarian Carcinoma — Trials

Platinum-Sensitive Ovarian Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

26 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 7
Ph III recruiting: 2
Growth YoY: —
Industry share: 33%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01847274	A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer	completed	Phase 3	596	Tesaro, Inc.INDUSTRY	15	Jun 2, 2023	clinicaltrials
NCT01837251	Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer	completed	Phase 3	682	AGO Research GmbHINDUSTRY	6	Jul 13, 2021	clinicaltrials